Sinovac Biotech (NASDAQ: SVA) reshapes board committees and creates Litigation Committee

Rhea-AI Filing Summary

Sinovac Biotech Ltd. reported that its Board met on August 19, 2025 and refreshed several governance structures. The Board confirmed seven directors, including Andrew Yan and Simon Anderson, as independent under Nasdaq rules.

The Board appointed Simon Anderson and Yuk Lam Lo to the Audit Committee, with Anderson as chair, and amended the Audit Committee Charter to reduce the minimum size from three to two members, consistent with home-country practice for a foreign private issuer. It also named new members and chairs for the Compensation Committee and the Nominating and Governance Committee, and created a Litigation Committee of independent directors to evaluate claims in certain legal proceedings and make recommendations to the Board.

Insights

Corporate governance analyst

Sinovac updates board committees and forms a new litigation body.

Sinovac Biotech Ltd. clarified that seven directors meet Nasdaq independence standards and reshaped its key board committees. The Audit Committee now has two independent members, with Simon Anderson as chair, after an amendment allowing a smaller committee consistent with home-country practice.

The Compensation and Nominating and Governance Committees gained clearly identified independent members and chairs, which can support more structured oversight of pay and director selection. A new Litigation Committee of independent directors will review and evaluate claims in certain legal proceedings and advise the full Board.

These steps formalize oversight roles without disclosing financial impacts. Future company filings may describe how the Litigation Committee’s evaluations influence resolutions of the referenced legal proceedings or any related governance changes.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-32371

SINOVAC BIOTECH LTD.

No. 39 Shangdi Xi Rd, Haidian District

Beijing 100085, People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒         Form 40-F ☐

The Board of Directors (the “Board”) of Sinovac Biotech Ltd. (the “Company”), a leading provider of biopharmaceutical products in China, held a meeting on August 19, 2025 (China Standard Time), and approved the following matters:

Director Independence

The Board determined that Mr. Andrew Yan, Mr. Shan Fu, Mr. Yumin Qiu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yu Wang and Mr. Simon Anderson were each independent directors under the rules of the Nasdaq Stock Market (“Nasdaq”).

Audit Committee Appointment

The Board appointed Mr. Simon Anderson and Mr. Yuk Lam Lo as members of the Audit Committee. Mr. Anderson has been appointed to serve as the chairperson of the Audit Committee. Each such director satisfies the enhanced independence requirements for the Audit Committee.

The Board approved an amendment to the Company’s Audit Committee Charter to reduce the minimum number of required members from three to two. As a foreign private issuer, the Company is permitted to follow its home country practices with respect to the audit committee which do not require that an audit committee have three members. Each member of the Audit Committee will continue to satisfy the applicable independence and qualification requirements under the rules of Nasdaq and the U.S. Securities Exchange Act of 1934, as amended.

Compensation Committee Appointment

The Board appointed Mr. Andrew Yan, Mr. Shan Fu and Mr. Yuk Lam Lo as members of the Compensation Committee. Mr. Lo has been appointed to serve as the chairperson of the Compensation Committee.

Nominating and Governance Committee Appointment

The Board appointed Mr. Andrew Yan, Mr. Yumin Qiu and Mr. Yu Wang as members of the Nominating and Governance Committee. Mr. Yan has been appointed to serve as the chairperson of the Nominating and Governance Committee.

Litigation Committee Formation and Appointment

The Board approved the formation of a Litigation Committee, which is authorized to investigate and evaluate claims and allegations asserted in certain legal proceedings involving the Company, and to make recommendations to the Board with respect to such matters. The Litigation Committee will be composed of Mr. Andrew Yan and Mr. Yuk Lam Lo, with Mr. Yan serving as the chairperson.

Safe Harbor Statement

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s or Board’s control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINOVAC BIOTECH LTD.
	By:	/s/ Andrew Y. Yan
	Name:	Andrew Y. Yan
	Title:	Chairman of the Board

Date: August 21, 2025

2

FAQ

What corporate governance changes did Sinovac Biotech Ltd. (SVA) announce?

Sinovac Biotech Ltd. reported multiple governance updates, including refreshed committee memberships and a new Litigation Committee. The Board confirmed seven Nasdaq-independent directors, reshaped the Audit, Compensation, and Nominating and Governance Committees, and established a Litigation Committee of independent directors to evaluate certain legal proceedings.

Which Sinovac Biotech Ltd. (SVA) directors were deemed independent by the Board?

The Board determined that Andrew Yan, Shan Fu, Yumin Qiu, Shuge Jiao, Yuk Lam Lo, Yu Wang, and Simon Anderson are independent directors under Nasdaq rules. This confirmation supports the composition of Sinovac’s key board committees, including audit, compensation, nominating and governance, and the newly formed Litigation Committee.

How did Sinovac Biotech Ltd. (SVA) change its Audit Committee structure?

Sinovac Biotech Ltd. appointed Simon Anderson and Yuk Lam Lo to the Audit Committee, with Anderson as chair. The Board amended the Audit Committee Charter to reduce the minimum required members from three to two, aligning with home-country practices available to foreign private issuers under applicable rules.

What is the new Litigation Committee at Sinovac Biotech Ltd. (SVA)?

The Board created a Litigation Committee authorized to investigate and evaluate claims and allegations in certain legal proceedings involving Sinovac. Composed of Andrew Yan and Yuk Lam Lo, with Yan as chair, it will make recommendations to the Board regarding these matters and related responses.

Who serves on Sinovac Biotech Ltd. (SVA) Compensation and Nominating Committees?

The Compensation Committee now includes Andrew Yan, Shan Fu, and Yuk Lam Lo, with Lo as chair. The Nominating and Governance Committee includes Andrew Yan, Yumin Qiu, and Yu Wang, with Yan as chair, clarifying leadership and membership of Sinovac’s key oversight committees.